Between the two of us, we have been involved in pediatrics for over 70 years. The changes that have occurred reflect many of the changes in medicine as a whole, but in some ways they have exceeded the advances in adult medicine. Along with our growing knowledge of the mechanisms of growth and development, both in health and in disease, and of the underlying pathophysiology of many of the conditions we had catalogued but failed to comprehend through the years, our interventions have vastly changed. The underlying science, the practicalities of medical product evaluation, and the regulatory science needed to ensure the effectiveness and safety of medicines and devices all continue to evolve. However, the evolution is not infrequently ''out of sync,'' challenging us to ensure at all phases that we understand what is happening in all others. We must work together to close the gaps between basic knowledge and real treatments.
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In this issue of TIRS, we have a special section on pediatrics and a series of articles highlighting the challenges and opportunities we face. At the very threshold of life, we have seen remarkable advances in survival of our tiniest premature infants, yet they face very special conditions leading to mortality and morbidities in the short and long term. Most of the drugs used in this population have not had a rigorous evaluation of age-specific dose, safety, and efficacy. Thus, PDUFA-V included emphasis on neonatal therapeutics, and efforts are underway internationally to develop the needed global infrastructure to advance understanding of neonatal conditions and novel interventions. In this issue, Offringa et al examine a new initiative of the Critical Path Institute along with FDA, EMA, academe, and industry to move neonatology forward, and hopefully to develop a new generation of medicine specifically targeted at diseases of the newborn.
A crucial ''job'' of childhood is growth and development, and when central nervous system (CNS) diseases intervene, the tragedy is obvious. We continue to struggle to understand and to manage pediatric neurologic and psychiatric diseases. We have 2 papers in this issue that deal with very different but related aspects. Connolly et al address the complexities of molecular etiologies and gene networks in the etiology and pathogenesis of pediatric CNS conditions. The remarkable advances in understanding complex genomic and metabolomics pathways are beginning to revolutionize the specificity of diagnosis of conditions we previously lumped together, and they are also suggesting novel ways to discovery and develop new targeted therapeutics. A huge challenge in CNS conditions is accurate and meaningful definition of ''phenotype.'' Drury and Cuthbert describe efforts at creating a new research nosology of mental diseases, new ways of classifying mental disorders based on behavioral dimensions, and new neurobiological measures. Functional aspects of behavior cross traditional diagnostic categories, including in children. As we explore new targeted therapies, we are likely to find overlapping benefit among our old disease classifications. The RDOC effort at NIMH is evolving, and the discussion of how to classify mental illnesses, how to enter patients into clinical trials, and how to develop and label new drugs will continue to evolve as well. Introducing these concepts, from the molecular through the behavioral into pediatric drug development, will be vital to future success. Some aspects of pediatric research, for example increased engagement of patients throughout the process of discovery and development of medical products, are increasingly aligned with trends in adult investigation. Patient-centricity has been discussed extensively in the adult world, but Hadleigh Thompson et al provide us insight into an exciting global initiative involving children and indeed led by children. Much advocacy revolves around specific diseases or conditions; here we see children per se, those who are healthy and those who are ill or who have participated in a clinical trial, working together to understand and to support biomedical research.
Another aspect of therapeutics in children is rather different than in adults: the need for pediatric specific formulations to accurately, safely, effectively, and adherently administer drugs to children of varying ages. Charles Thompson et al provide recommendations for best practices in assessing the palatability and swallowability of oral dosage forms in pediatrics. As parents, we are well aware of the challenges of administering medicines to our own children, and as physicians we so often see the problems associated with the need to chronically administer Pediatric device development can be challenging, but it also offers potentially remarkable outcomes for children. Fisher et al discuss regulatory and funding strategies to develop a safety study of an auditory brainstem implant in young children.
And through it all, further evaluation of regulatory science is needed as other aspects of pediatric drug development change. The article by Tabor examines current FDA requirements of clinical studies in pediatric patients. This arena could easily occupy an enter issue of TIRS and beyond. Legislation-Best Pharmaceuticals for Children Act, Pediatric Research Equity Act, ''Creating Hope Act''; guidance-ICH E-11; and Regulation-EU pediatrics incentives and requirements-have evolved over the years. Sometimes, scientific advances seem to outpace legislative and regulatory approaches, yet we have seen the power of raising the priorities of children's needs through requirements and incentives. We continue to struggle to achieve the spirit of ICH E-11 with true global harmonization. Essentially all pediatric clinical studies need to recruit patients globally. It seems pretty clear that duplicative studies are both ethically and practically undesirable and unwarranted if we can ensure the highest scientific standards through increased harmonization.
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